Gannon Steven's Form 4 filing
Xenon Pharmaceuticals Inc. (XENE) · filed Jun 6, 2025
- Accession no.
- 0000950170-25-083321
- Filed
- Jun 6, 2025
- Trade date
- Jun 5, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market sales total $91.44. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gannon StevenCIK 0001643085 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2025 | Common Shares | SSaleDisposed | −3 | $30.48 | −$91.44 | 7,141 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2025 | Common Shares | AGrant or awardAcquired | +17,012 | $0.00 | $0 | 17,012 | Direct | |
| Jun 5, 2025 | Common Shares | AGrant or awardAcquired | +2,645 | $0.00 | $0 | 2,645 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.